September 8, 2018
Written by Savas Abadsidis
The FDA has approved Pifeltro (doravirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), as well as Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate), which includes the first medication in a three-drug, single-tablet regimen.
George Hanna, vice president and therapeutic area head of infectious diseases, global clinical development, Merck Research Laboratories, said in a press release: “As part of Merck’s 30-year commitment to the care of people with HIV, we are pleased to now bring forward these two new antiretroviral treatment options, Delstrigo and Pifeltro, which we believe offer a compelling clinical profile for clinicians and people living with HIV.”
Both drugs, administered orally once daily, are indicated for the treatment of HIV in adult patients with no prior antiretroviral in combination with other HIV medications.